viagenpumatucel-L + pembrolizumab + pemetrexed

A combination therapy approach for non-small cell lung cancer (NSCLC) that would theoretically combine viagenpumatucel-L (HS-110), an allogeneic cell-based therapeutic cancer vaccine derived from a human lung adenocarcinoma cell line incorporating multiple cancer testis antigens and transfected with a gp96-Ig fusion protein, with pembrolizumab, a PD-1 inhibitor, and pemetrexed, a folate antimetabolite chemotherapy agent. While clinical trials have evaluated HS-110 with nivolumab and separately pembrolizumab with pemetrexed, there is no specific evidence in the provided search results of all three agents being studied together in a single regimen.